Product
FT536
Aliases
NK Cell Therapy
2 clinical trials
10 indications
Indication
Lung CancerIndication
Colorectal CancerIndication
Breast CancerIndication
Ovarian CancerIndication
Pancreatic CancerIndication
Head and Neck CancerIndication
Gastric Esophageal CancerIndication
Gynecologic CancerIndication
Fallopian tube cancerIndication
Primary Peritoneal Cavity CancerClinical trial
A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-08-11
Clinical trial
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerStatus: Not yet recruiting, Estimated PCD: 2028-06-30